^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAT8007

    i
    Other names: BAT8007
    Associations

    News

    Trials
    Company:
    Bio-Thera Solutions
    Drug class:
    Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3ms
    BAT-8007-001-CR: To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=250, Recruiting, Bio-Thera Solutions | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    BAT8007
    1year
    To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=250, Recruiting, Bio-Thera Solutions | N=42 --> 250
    Enrollment change • Metastases
    |
    BAT8007
    2years
    To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, Bio-Thera Solutions
    New P1 trial • Metastases
    |
    BAT8007